Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 7/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5233222 | 0.94 | DPP4 (0.46) | DPP4ABCB11GABRA1GABRG2GABRB3 | |
| SCHEMBL5241273 | 0.87 | DPP4 (0.48) | DPP4ABCB11GABRA1GABRG2GABRB3 | |
| Hydrochloric Acid SCHEMBL5237333 | 0.86 | DPP4 (0.60) | DPP4ABCB11GABRA1GABRG2GABRB3 | |
| SCHEMBL5236683 | 0.84 | DPP4 (0.45) | DPP4GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL5237536 | 0.83 | DPP4 (0.44) | DPP4GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL5236325 | 0.82 | ABCB11 (0.47) | DPP4ABCB11GABRA1GABRG2GABRB3 | |
| SCHEMBL5239041 | 0.81 | DPP4 (0.51) | DPP4GABRA1GABRG2GABRB3GABRA5 | |
| Hydrochloric Acid SCHEMBL5240978 | 0.81 | DPP4 (0.56) | DPP4ABCB11CYP3A4 | |
| SCHEMBL5232739 | 0.80 | DPP4 (0.47) | DPP4GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL5238796 | 0.79 | DPP4 (0.58) | DPP4GABRA1GABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355886-B1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-7034039-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-25 | — | — | US | disclosed |
| US-20040082607-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1355886-A1 | FUSED HETEROCYCLIC COMPOUNDS | Takeda Chemical Industries, Ltd. (JP) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002062764-A9 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-10-10 | — | — | WO | disclosed |
| WO-2002062764-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082607-A1 | Fused heterocyclic compounds | DPP7, DPP4, METAP1 | DPP4 2/4885ABCB11 1946/4885GABRA1 3124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.